Given the number of comorbidities associated with obesity, the market's growth will impact the entire cardiometabolic disease ...

Lilly will provide an initial payment to complete a Phase I trial of OLX75016, which started in February 2024.

Compounding pharmacies aren’t the only makers of off-brand versions of Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound. The ...

Yes, rare cases of vision issues have arisen in people taking popular GLP-1 weight loss drugs, but the jury's out on whether ...

The next FDA Commissioner could solve two big problems with one powerful policy: encourage independent testing of both ...

Ozempic and other glucagon-like peptide-1 (GLP-1) agonists are a transformative new class of medicines for the treatment of diabetes and obesity, while also delivering other health benefits, such as ...

Ozempic and Wegovy maker Novo Nordisk placed a print ad responding to the Super Bowl spot from competitor Hims & Hers.

A new study published in JAMA Ophthalmology reveals that weight loss drugs like Ozempic and similar medications could cause ...

We recently compiled a list of the 13 Best Dividend Growth Stocks With 10%+ Yearly Increases. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against ...

“The first thing they see is the loose skin on their abdomen," says R. Brannon Claytor, a Bryn Mawr, Pa.-based plastic ...

Discover why people risk buying Ozempic and similar weight loss medications through social media, the devastating consequences, and legitimate ways to treatment ...

At medical conferences and hospital cafeterias, one thing has become increasingly clear—many doctors are using Ozempic, ...